That’s not surprising because throughout the pandemic, communications regarding the Pfizer-BioNTech Covid-19 vaccines have deserved an F grade. It’s been far too F-word upped, relied far too ...

Pfizer (NYSE:PFE) on Thursday reported top-line efficacy and safety data for its Abrysvo vaccine for respiratory syncytial ...

Representatives for Pfizer and BioNTech did not immediately respond to requests for comment. Moderna accused Pfizer and BioNTech's vaccine of violating its patent rights in messenger-RNA ...

An RSV vaccine already used for older adults could help protect people as young as 18 who are at increased risk of the disease, drugmaker Pfizer said in a news release Tuesday. The company said ...

Pfizer (NYSE:PFE) seems to be one of these companies, where the combination of recent share price declines and a steadily growing dividend had caused the company's yield to eclipse the 6% level.

Over the last twelve months, Pfizer's stock experienced a massive sell-off due to a massive revenue and EPS drop after the COVID-related spikes of 2021 and 2022. However, the company's financial ...

The drugmaker raised its earnings guidance for the year. (Tony Luong for The Wall Street Journal) Pfizer shares rose more than 6% Wednesday afternoon after the company's first-quarter results beat ...

Pfizer will retool its obesity drug efforts, but the delay is a blow to the group's ambitions to challenge Novo Nordisk and Lilly in the fast-developing space. Pfizer (PFE) shares slumped ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on ...

(Bloomberg) -- Pfizer Inc. plans to sell about £2 billion ($2.5 billion) of shares in Haleon Plc, the first step by the UK ...

Pfizer Prospects Garner Mixed Sentiment From Analysts: 'Finally, The Pivot Investors Have Been Waiting For' Pfizer analysts from Goldman see a positive outlook on Padcev, Prevnar, and Vindaqel ...

Sales of Padcev, a treatment for advanced bladder cancer Pfizer gained through its $43 billion deal for Seagen, also came in ahead of analysts' expectations. The Seagen deal, as well as its $4 ...